Cabaletta Bio (CABA) Projected to Post Earnings on Monday

Cabaletta Bio (NASDAQ:CABA) will likely be posting its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Cabaletta Bio to post earnings of ($0.45) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, April 3, 2026 at 8:00 AM ET.

Cabaletta Bio Trading Down 3.3%

Shares of NASDAQ CABA opened at $2.94 on Monday. Cabaletta Bio has a 12 month low of $0.99 and a 12 month high of $3.78. The stock has a 50 day moving average of $2.85 and a 200-day moving average of $2.53. The company has a market capitalization of $283.00 million, a P/E ratio of -1.16 and a beta of 3.24.

Insider Activity at Cabaletta Bio

In other news, CEO Steven Nichtberger bought 45,000 shares of the stock in a transaction dated Wednesday, January 21st. The shares were bought at an average price of $2.24 per share, for a total transaction of $100,800.00. Following the completion of the purchase, the chief executive officer owned 1,031,483 shares in the company, valued at approximately $2,310,521.92. This trade represents a 4.56% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Steve Gavel bought 22,170 shares of the stock in a transaction dated Wednesday, January 21st. The shares were purchased at an average price of $2.27 per share, for a total transaction of $50,325.90. Following the purchase, the insider owned 22,170 shares of the company’s stock, valued at $50,325.90. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 127,668 shares of company stock valued at $286,211. 11.25% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CABA. OMERS ADMINISTRATION Corp bought a new stake in shares of Cabaletta Bio in the fourth quarter valued at about $209,000. Qube Research & Technologies Ltd bought a new position in Cabaletta Bio during the third quarter worth about $209,000. XTX Topco Ltd bought a new position in Cabaletta Bio during the second quarter worth about $148,000. Dynamic Technology Lab Private Ltd acquired a new stake in Cabaletta Bio in the 4th quarter worth about $146,000. Finally, Quadrature Capital Ltd raised its stake in Cabaletta Bio by 54.7% in the 4th quarter. Quadrature Capital Ltd now owns 66,377 shares of the company’s stock worth $145,000 after purchasing an additional 23,465 shares in the last quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cabaletta Bio in a report on Wednesday, January 21st. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.25.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.